FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947930157> ?p ?o ?g. }

• W2947930157 abstract "2534 Background: Antigen escape relapse has emerged as a major challenge for long-term disease control post CD19-directed therapies, to which dual-targeting of CD19 and CD22 has been proposed as a potential solution. Methods: Between Mar 2016 and Jan 2018, we conducted a pilot study (ChiCTR-OPN-16008526) in 38 patients (pts), who had refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), to evaluate the efficacy and safety of sequential infusion of anti-CD19 and anti-CD22, two single-specific, third-generation CAR19/22 T-cell “cocktail”. The cutoff date for data collection was Apr 30, 2018. Results: At a minimum follow-up of 3 months (mos), 26 of the 36 evaluable pts achieved an overall response (ORR), including 18 with a complete response (CR) and 8 with a partial response (PR). The ORR at mo 3 was consistent in different subgroups, irrespective of pathologic subtypes, cell of origin, cytogenetic or genomic aberrations. At the data cutoff, 15 of the 18 pts who had a CR at mo 3 maintained their responses, 2 of 8 pts who had a PR within 3 mos continued to have a CR without additional therapies. Collectively, the best ORR was 83.3%, with a best CR rate of 55.5% and a best PR rate of 27.8%. With a median follow-up of 5.3 mos (range, 0.4 to 16.2), the median PFS was 5.8 mos, and the median OS was not reached (NR). Pts received therapy at first relapse had better PFS than those who received therapy at the time with primary refractory diseases or at multiple relapses. Notably, pts who achieved an overall response at mo 3 (R3m) had significantly extended PFS and OS when compared with pts who did not. Repeated biopsy and IHC was conducted in 3 of the 13 pts. However, loss of CD19 or CD22 was not detected. Of the 9 pts with IgH/MYC translocation, with a median follow-up of 10.1 mos, the median PFS and median OS were NR. At data cutoff, 7 pts who had achieved R3m maintained their responses, including all the 4 pts with double-hit lymphoma. However, of the 10 pts with del(17p) or TP53 mutation, with a median follow-up of 5.3 mos (range, 2.7 to 14.5), the median PFS was 3.6 mos and the median OS was 9.9 mos. All pts experienced reversible CRS, with 21.1% were of high-grade. Neurotoxicity developed in 13.2% pts and were all low-grade. Conclusions: Our results indicated that sequential infusion of CAR19/22 T-cell is efficient and safe for pts with B-NHL. Dual antigen targeting is a promising approach to circumvent antigen loss relapse after CAR T-cell therapy. The impact of genetic subtypes and clinical parameters further underscores the critical importance of personalized immunotherapies. Clinical trial information: ChiCTR-OPN-16008526." @default.
• W2947930157 created "2019-06-07" @default.
• W2947930157 creator A5013697702 @default.
• W2947930157 creator A5016614811 @default.
• W2947930157 creator A5019762150 @default.
• W2947930157 creator A5025704945 @default.
• W2947930157 creator A5028465455 @default.
• W2947930157 creator A5055807567 @default.
• W2947930157 creator A5067382998 @default.
• W2947930157 creator A5083120274 @default.
• W2947930157 creator A5090728786 @default.
• W2947930157 date "2019-05-20" @default.
• W2947930157 modified "2023-09-23" @default.
• W2947930157 title "Efficacy and safety of CAR19/22 T-cell “cocktail” therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma." @default.
• W2947930157 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.2534" @default.
• W2947930157 hasPublicationYear "2019" @default.
• W2947930157 type Work @default.
• W2947930157 sameAs 2947930157 @default.
• W2947930157 citedByCount "0" @default.
• W2947930157 crossrefType "journal-article" @default.
• W2947930157 hasAuthorship W2947930157A5013697702 @default.
• W2947930157 hasAuthorship W2947930157A5016614811 @default.
• W2947930157 hasAuthorship W2947930157A5019762150 @default.
• W2947930157 hasAuthorship W2947930157A5025704945 @default.
• W2947930157 hasAuthorship W2947930157A5028465455 @default.
• W2947930157 hasAuthorship W2947930157A5055807567 @default.
• W2947930157 hasAuthorship W2947930157A5067382998 @default.
• W2947930157 hasAuthorship W2947930157A5083120274 @default.
• W2947930157 hasAuthorship W2947930157A5090728786 @default.
• W2947930157 hasConcept C126322002 @default.
• W2947930157 hasConcept C142424586 @default.
• W2947930157 hasConcept C143998085 @default.
• W2947930157 hasConcept C159654299 @default.
• W2947930157 hasConcept C203014093 @default.
• W2947930157 hasConcept C2778453870 @default.
• W2947930157 hasConcept C2779338263 @default.
• W2947930157 hasConcept C502942594 @default.
• W2947930157 hasConcept C71924100 @default.
• W2947930157 hasConcept C86803240 @default.
• W2947930157 hasConcept C87355193 @default.
• W2947930157 hasConceptScore W2947930157C126322002 @default.
• W2947930157 hasConceptScore W2947930157C142424586 @default.
• W2947930157 hasConceptScore W2947930157C143998085 @default.
• W2947930157 hasConceptScore W2947930157C159654299 @default.
• W2947930157 hasConceptScore W2947930157C203014093 @default.
• W2947930157 hasConceptScore W2947930157C2778453870 @default.
• W2947930157 hasConceptScore W2947930157C2779338263 @default.
• W2947930157 hasConceptScore W2947930157C502942594 @default.
• W2947930157 hasConceptScore W2947930157C71924100 @default.
• W2947930157 hasConceptScore W2947930157C86803240 @default.
• W2947930157 hasConceptScore W2947930157C87355193 @default.
• W2947930157 hasLocation W29479301571 @default.
• W2947930157 hasOpenAccess W2947930157 @default.
• W2947930157 hasPrimaryLocation W29479301571 @default.
• W2947930157 hasRelatedWork W2789714273 @default.
• W2947930157 hasRelatedWork W2799363177 @default.
• W2947930157 hasRelatedWork W2889880002 @default.
• W2947930157 hasRelatedWork W2892131121 @default.
• W2947930157 hasRelatedWork W2922457232 @default.
• W2947930157 hasRelatedWork W2934961572 @default.
• W2947930157 hasRelatedWork W2942971574 @default.
• W2947930157 hasRelatedWork W2952585764 @default.
• W2947930157 hasRelatedWork W2986232810 @default.
• W2947930157 hasRelatedWork W3014049381 @default.
• W2947930157 hasRelatedWork W3014063532 @default.
• W2947930157 hasRelatedWork W3030863102 @default.
• W2947930157 hasRelatedWork W3036563482 @default.
• W2947930157 hasRelatedWork W3041720367 @default.
• W2947930157 hasRelatedWork W3093575130 @default.
• W2947930157 hasRelatedWork W3168168786 @default.
• W2947930157 hasRelatedWork W3170494781 @default.
• W2947930157 hasRelatedWork W3180238237 @default.
• W2947930157 hasRelatedWork W3212584825 @default.
• W2947930157 hasRelatedWork W3125708985 @default.
• W2947930157 isParatext "false" @default.
• W2947930157 isRetracted "false" @default.
• W2947930157 magId "2947930157" @default.
• W2947930157 workType "article" @default.